Every 10-Q that Axogen, Inc. (AXGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AXGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AXGN filings page.
Axogen, Inc. reported strong top-line growth but a GAAP loss for the period. Revenue was $69,731 (in thousands) for the quarter ended June 30, 2026, up 23.1% year over year, and $131,188 (in thousands) for the first six months, up 24.7%. Quarterly gross margin was 72.7%, slightly below 74.2% a year earlier as higher-cost biologic Avance products and longer grafts increased product costs.
The company posted a quarterly net loss of $1,516 (in thousands) and a six‑month net loss of $21,100 (in thousands), largely driven by a $16,849 (in thousands) loss on extinguishment of debt tied to the January 2026 payoff of its Oberland credit facility. Net proceeds of $133,252 (in thousands) from a 4.6 million‑share equity offering at $31.00 per share were used to pay a $69,707 (in thousands) payoff amount and terminate the facility, eliminating $48,387 (in thousands) of long‑term debt and related derivatives.
Cash, cash equivalents and investments rose to $111,412 (in thousands) at June 30, 2026, from $41,528 (in thousands) at year‑end, and the current ratio improved to 6.6x. Operating cash flow turned positive at $8,786 (in thousands). Operating expenses increased 32.4% year to date to support sales expansion, higher stock‑based compensation of $15,609 (in thousands), and clinical programs such as Nerve‑RESTORE. Subsequent to quarter‑end, Axogen invested $7,000 (in thousands) in Trace Biosciences, gaining a minority stake and limited right of first refusal on nerve‑specific imaging technology.
Axogen, Inc. reported strong top-line growth but a larger net loss for the quarter ended March 31, 2026. Revenue rose to $61,457, up 26.6% from the prior year period, driven mainly by higher unit volumes and pricing.
Gross profit increased to $46,189 and gross margin improved to 75.2%, helped by lower inventory write-offs and shipping costs. Operating expenses grew to $49,021 as the company expanded sales, marketing and R&D, resulting in a loss from operations of $2,832.
Net loss widened to $19,584, largely due to a $16,849 loss on extinguishment of debt after Axogen used $69,707 of proceeds from a $133,252 equity offering to repay and terminate its Credit Facility. Cash, cash equivalents and investments increased to $101,601, and management believes this liquidity and product sales will fund operations for at least the next twelve months.
Axogen (AXGN) reported Q3 2025 results. Revenue was $60,082, up 23.5% year over year, with gross profit of $45,993 and gross margin of 76.6%. The quarter delivered net income of $708 (diluted EPS $0.01) versus a loss a year ago, as sales and marketing investments supported higher volumes and pricing.
For the first nine months, revenue reached $165,304 and net loss was $2,547. Cash, cash equivalents and investments totaled $35,791 as of September 30, 2025. Management noted that discontinuing the Avance case stock program and moving some customers to direct orders increased Q3 revenue by about $1.6 million.
Industry tailwinds included new society statements from AAHS and ASRM recognizing nerve allograft as a standard option and broader payer coverage, adding approximately 18.1 million covered lives in 2025. The FDA accepted the BLA for Avance Nerve Graft and, after a major amendment, set a December 5, 2025 PDUFA goal date.